Asia wins 2017’s mid-cap race
A cooling of the M&A climate allows Asia-based groups to come to the fore.
Back to the future for small caps, but not all benefit
Oncology-focused smaller biotechs reap rich rewards, but generics groups face hard times.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.